Premal Lulla, MD, assistant professor of medicine at the Center for Cell and Gene Therapy, Texas Children's Hospital, discusses the need for cellular therapies for patients with leukemia after transplant.

Patients who relapse posttransplant have a very poor prognosis, says Lulla. In this setting, there are no approved treatment options in the frontline setting.

Lulla believes the posttransplant environment has room for immunotherapy to improve outcomes. 

2019 Transplantation and Cellular Therapy Meetings

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Transplantation and Cellular Therapy Meetings

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Dr. Lulla Discusses Post-Transplant Options for Leukemias